Literature DB >> 29158137

Recent developments in the management of bladder cancer: Introduction.

Angela B Smith1.   

Abstract

An upsurge of advances in the management of bladder cancer has rapidly occurred over the past 2 years. In this issue, recent developments in the management of bladder cancer will be discussed, including the emerging role of immunotherapy, biomarkers, and advanced imaging.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29158137     DOI： 10.1016/j.urolonc.2017.10.026

Source DB:  PubMed          Journal:  Urol Oncol        ISSN： 1078-1439            Impact factor:   3.498


  7 in total

1.  MiR-582-5p Inhibits Bladder Cancer-Genesis by Suppressing TTK Expression.

Authors:  Yudong Tian; Yanbin Guan; Yang Su; Wenjian Luo; Guo Yang; Yu Zhang
Journal:  Cancer Manag Res       Date:  2020-11-20       Impact factor: 3.989

2.  GSG2 (Haspin) promotes development and progression of bladder cancer through targeting KIF15 (Kinase-12).

Authors:  Yuhao Chen; Dian Fu; Hai Zhao; Wen Cheng; Feng Xu
Journal:  Aging (Albany NY)       Date:  2020-05-21       Impact factor: 5.682

3.  Neural precursor cell expressed, developmentally downregulated 8 promotes tumor progression and predicts poor prognosis of patients with bladder cancer.

Authors:  Da-Wei Tian; Zhou-Liang Wu; Li-Ming Jiang; Jie Gao; Chang-Li Wu; Hai-Long Hu
Journal:  Cancer Sci       Date:  2018-12-10       Impact factor: 6.716

4.  Long Non-Coding RNA BCAR4 Binds to miR-644a and Targets TLX1 to Promote the Progression of Bladder Cancer.

Authors:  Xiaojing Wang; Hongchao He; Wenbin Rui; Xin Xie; Dawei Wang; Yu Zhu
Journal:  Onco Targets Ther       Date:  2020-03-24       Impact factor: 4.147

5.  Overexpression of miR-340 inhibits cell proliferation and induces apoptosis of human bladder cancer via targeting Glut-1.

Authors:  Gang Xu; Shouhua Pan; Zhirong Zhu; Junlong Li
Journal:  BMC Urol       Date:  2021-12-03       Impact factor: 2.264

6.  Magnesium isoglycyrrhizinate suppresses bladder cancer progression by modulating the miR-26b/Nox4 axis.

Authors:  Zhihao Yuan; Guancheng Guo; Guifang Sun; Qi Li; Lihui Wang; Baoping Qiao
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

7.  DEPDC1B is a tumor promotor in development of bladder cancer through targeting SHC1.

Authors:  Chin-Hui Lai; Kexin Xu; Jianhua Zhou; Mingrui Wang; Weiyu Zhang; Xianhui Liu; Jie Xiong; Tao Wang; Qi Wang; Huanrui Wang; Tao Xu; Hao Hu
Journal:  Cell Death Dis       Date:  2020-11-17       Impact factor: 8.469
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.